EPM News Update
Particle Sciences has teamed up with NETZSCH Premier Technologies to provide drug developers with improved access to state-of-the-art pharmaceutical nanomilling equipment and full pharmaceutical development capabilities.
According to Robert Lee, PhD, Vice President Pharmaceutical Development, “Particle Sciences has been using particle size reduction — in both dry and liquid-dispersed states — for decades. With this collaboration, we acquired a NETZSCH DELTAVITA Mill, which is one of the premier systems for pharmaceutical applications. There is a growing demand for wet-milled products, particularly with respect to sterile products. In fact, we are currently working on approximately 20 milling projects; the majority being sterile products. The additional capability allows our clients to get into the clinic faster with a commercially representative manufacturing process.”
Particle Sciences focuses on commercially-ready, advanced drug delivery technologies and is FDA registered and licensed for all schedules of controlled substances. Randall Smith, President of NETZSCH Premier Technologies, added: “Particle Sciences provides customers that are interested in wet milling access to full development capabilities, including being able to take their products from feasibility into preclinical testing, then ultimately human clinical trials and commercialisation. They will be a valuable partner to fully demonstrate the utility of our equipment and we will work with them as they continue to expand.”
Particle Sciences, +1 610 861 4701, mmattera@particlesciences.com, www.particlesciences.com.